Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
Research ArticleClinical Review

Prescribing for common complications of spinal cord injury

Mary Ann McColl, Shikha Gupta, Alexander McColl and Karen Smith
Canadian Family Physician December 2022, 68 (12) 885-888; DOI: https://doi.org/10.46747/cfp.6812885
Mary Ann McColl
Professor in the Department of Public Health Sciences and the School of Rehabilitation Therapy at Queen’s University in Kingston, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mccollm@queensu.ca
Shikha Gupta
Research Coordinator in the School of Rehabilitation Therapy at Queen’s University.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander McColl
Associate Professor and retired Head of Port Macquarie Rural Medical School, University of New South Wales, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen Smith
Professor Emerita in the Faculty of Health Sciences at Queen’s University.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Abstract

Objective To describe prescribing patterns for 3 common complications associated with spinal cord injury (SCI) and to provide family doctors with strategies for optimizing the care of patients with SCI.

Sources of information Results of a nationwide survey of prescription medication use among people with SCI in Canada and a longitudinal study of secondary complications associated with SCI.

Main message Altered neurologic and cardiometabolic function in patients with SCI make it difficult for family physicians to predict optimal medication regimens for these patients. Three common problems seen in primary care among patients with SCI that require pharmacologic treatment are pain (treated in 57% of survey respondents), muscle spasms (54%), and recurrent urinary tract infections (43%). Pain management may require multiple medications, depending on the source or nature of the pain. Some prescription medications recommended for treating pain may be underused in this population, such as amitriptyline, while others may be overused in this population, such as antibiotics for urinary tract infections. Spasticity is often related to an underlying problem such as pain, and treatment of concomitant conditions may also reduce spasticity. Short-acting benzodiazepines were found to have been prescribed for spasticity outside the recommended treatment paradigm at a surprisingly high rate. The longitudinal study of secondary complications associated with SCI led to the development of Actionable Nuggets, an innovative knowledge translation tool for primary care providers.

Conclusion To provide optimal treatment to patients with SCI, family doctors are encouraged to engage in open communication with them about prescription medications, including aspects of cost, polypharmacy, and therapeutic substitutions. Family physicians should also explore interprofessional collaboration with SCI specialists and allied health providers to provide patients with nonpharmacologic strategies tailored to their activity levels and nutritional needs. The Actionable Nuggets mobile app provides family doctors with brief, actionable, evidence-based information on the top 20 health concerns associated with SCI.

Spinal cord injury (SCI) is a condition where individual family physicians are likely to have only 1 affected patient among their practice population, making it challenging to provide the best evidence-based care. This is particularly evident when prescribing medications for clinical problems specific to SCI. This article provides a clinical review of prescribing patterns for the 3 most commonly treated complications associated with SCI.

Case description

You are seeing one of your regular patients, Devon, who was involved in a motor vehicle collision 2 years ago and has complete T8 SCI. During his appointment you identify 3 problems interfering with function:

  • He has burning pain in all areas below the level of his injury that is interfering with sleep.

  • In the past year he has contacted your office on 6 occasions reporting a temperature above 37.6°C and cloudy, sometimes bloody urine. Cultures you have ordered have consistently grown 1 primary organism.

  • Over the past 9 months Devon has found his spasticity has increased and is occasionally making it difficult for him to transfer into the car to get to work.

Sources of information

This review is based on the results of 2 studies by the authors. The first is a nationwide survey of prescription medication use among people with SCI in Canada.1 The survey was distributed with the assistance of 3 national community-based consumer advocacy and research organizations: the Rick Hansen Foundation, Spinal Cord Injury Canada, and the Canadian Spinal Research Organization. Of the 108 survey participants, 59 were male (55%); 87 individuals had traumatic SCI (80%); and 57 had paraplegia (53%) while 51 had tetraplegia (47%). The mean (SD) age of the participants was 48 (14) years, and the mean (SD) time since injury was 20 (12) years. The survey asked participants about their medication use (number and names of prescribed medications), demographic characteristics, and injury details.2 The study was approved by the Health Sciences Research Ethics Board at Queen’s University in Kingston, Ont.

The second study contributing to this review is a longitudinal study of secondary complications associated with SCI, resulting in an innovative knowledge translation tool called Actionable Nuggets.3,4 Actionable Nuggets is a mobile app designed specifically for family physicians, offering brief, actionable, evidence-based information on the top 20 health concerns associated with SCI.5

Main message

Three complications that required pharmacologic treatment among individuals with SCI were pain (treated in 57% of our sample), muscle spasms (54%), and recurrent urinary tract infections (UTIs, 43%).

Pain. As many as 8 types of pain are commonly associated with SCI, but by far the most prevalent and impactful is neuropathic pain, which is estimated to affect 75% of patients.6 A 4-item screening tool, the Spinal Cord Injury Pain Instrument, is recommended for distinguishing neuropathic from non-neuropathic pain. At a cut-off score of 2 out of 4 (50%), the Spinal Cord Injury Pain Instrument has sensitivity of 78%, specificity of 73%, and diagnostic accuracy of 76%.7

First-line agents for the treatment of chronic neuropathic pain in SCI according to the latest evidence are pregabalin, gabapentin, and amitriptyline,8,9 making up 51% of prescriptions issued for pain in our sample.

Tricyclic antidepressants (TCAs) are as effective as gabapentinoids for relief of neuropathic pain with SCI, but they may be poorly tolerated by some patients with SCI because of their anticholinergic side effects and their effect on cardiac conduction.8 Typically, the TCA dose required to achieve adequate pain relief in patients with SCI is below the threshold for anticholinergic side effects that would exclude their use.8 Tricyclic antidepressants are contraindicated for patients with glaucoma, symptomatic prostatism, and substantial cardiovascular disease.10

Of the TCAs (amitriptyline, nortriptyline, desipramine), amitriptyline is most commonly prescribed to patients with SCI because of its efficacy in relieving neuropathic pain.11 It is more likely than other TCAs to produce drowsiness,8 but this soporific effect can be quite useful, especially when neuropathic pain disrupts sleep. Amitriptyline had been prescribed to less than 10% of our sample population, perhaps suggesting underuse.

Second-line agents for the treatment of neuropathic pain in SCI are tramadol and lamotrigine.9 There is mixed evidence for third- and fourth-line agents, such as cannabinoids, botulinum toxin, and baclofen.8 There is no evidence in favour of clonidine (alone), mexiletine, levetiracetam, valproic acid, trazodone, or duloxetine.8,9 In our sample, approximately one-third of patients had been treated with second- or third-line agents.

Opioids had been prescribed for pain in 32% of our sample. While opioids have an important place in the treatment of pain, caution must be exercised due to increased risk of falls and reduced mobility.12 Concerns about opioid dependence and addiction can be addressed using clinical guidelines13 and other resources such as the Opioid Manager tool from McMaster University in Hamilton, Ont.14

Prescription for SCI-related pain is complex, especially given altered pharmacokinetics and multiple sources of pain (eg, neuropathic, degenerative, arthritic, inflammatory [acute and chronic], or visceral).15,16 Multiple medications may be required depending on the nature or source of the pain. Pain medication regimens need to be individualized according to source of pain and response to treatment.

Muscle spasms. As many as three-quarters of people with SCI experience spasticity, particularly those with lesions above T5.17 Uncontrolled spasticity can be a major obstacle to community integration, transportation, functional mobility, and personal and intimate relationships. Fifty-four percent of participants in our study had been treated for muscle spasms. The first-line pharmacologic management of spasms is oral or intrathecal baclofen,18 prescribed to 80% of those treated for muscle spasms in our sample. Other antispasmodic medications include cannabis, clonidine, cyproheptadine, dantrolene, diazepam, gabapentin, l-threonine, 4-aminopyridine, and tizanidine—all of which were used by less than 10% of individuals in our sample.

We were surprised to discover the extent to which short-acting benzodiazepines had been prescribed to treat spasticity. While these may be used short-term for intermittent problems with spasticity, they are not part of the recommended treatment paradigm because of their negative effects on individuals’ ability to void and ambulate.10,18,19

It should be noted that spasticity is often related to an underlying problem, such as a UTI or pain, thus treatment of concomitant conditions may also result in decreased spasticity.

Recurrent UTIs. Recurrent UTIs (>3 per year) are a major health concern among individuals with neurogenic bladder. They are often polymicrobial, antibiotic resistant, and caused by a wider variety of pathogens than are UTIs in the general population. Definitive diagnosis of UTI in patients with SCI requires 3 conditions: explicit signs and symptoms, substantial bacteriuria, and pyuria (≥50 white blood cells per high-power field).20,21

The most common medications prescribed to our survey respondents for UTIs were nitrofurantoins, making up 24% of the prescriptions issued for this condition, followed by cephalosporins (especially cephalexin; 20%). Other categories of drugs used to treat UTIs included fluoroquinolones (especially ciprofloxacin; 15%), β-lactams (eg, amoxicillin; 7%), trimethoprim-sulfamethoxazole (7%), and tetracyclines (7%).

There is no superior class of antibiotics, nor is there an evidence-based standard of care for antimicrobial treatment of UTI in patients with SCI. Guidelines for selecting antimicrobial agents include identification of the infecting organism and its antimicrobial susceptibility pattern, assessment of host resistance, and assessment of risk factors.22

There is a tendency to overtreat UTIs in patients with SCI, which contributes to antibiotic resistance. Asymptomatic infections and urine without substantial bacteriuria or pyuria should not be treated owing to a considerable risk of antimicrobial resistance. Antibiotics should not be offered for routine prophylaxis (eg, when changing indwelling catheters). The population of patients with SCI currently has higher resistance rates to a number of usual treatments for bladder infection, such as ampicillin, a combination of sulfamethoxazole and trimethoprim, and norfloxacin.23

Case resolution

Devon is prescribed amitriptyline at bedtime, which has been effective at reducing the burning pain he had been experiencing, and the sedating side effect is helping him sleep better at night.

Given the frequency of UTIs, you ask for a renal and bladder ultrasound, which does not reveal any underlying nephrolithiasis. The bladder did appear trabeculated. You review the bladder management protocol with Devon and discover he had stopped taking mirabegron and had reduced intermittent catheterization frequency, pointing to the need for open communication between patient and physician about medication prescriptions, including cost, polypharmacy, and therapeutic substitutions.24 You treat Devon for the current UTI based on the culture results, recommend resuming mirabegron, and review the clean no-touch technique for catheterization. You also help him obtain bladder management supplies through his work insurance plan so he can catheterize more regularly.

After making these changes, Devon’s spasticity reduces to the point that it no longer interferes with vehicular transfers, and no other intervention is necessary.

Conclusion

Medication management for patients with SCI is complex and specialized. Altered neurologic and cardiometabolic changes in patients with SCI make it difficult for family physicians to predict optimal medication regimens. This article highlights 3 commonly treated problems presenting in primary care among patients with SCI and data about the pharmacologic management of these issues. Strategies that can help family doctors to provide optimal treatment to their patients with SCI include open communication between patient and physician about medication prescriptions (including cost, polypharmacy, and therapeutic substitutions); interprofessional collaboration with SCI specialists and allied health providers to provide alternative (nonpharmacologic) strategies based on the patient’s physical activity, nutrition, and lifestyle management; and the Actionable Nuggets mobile app that provides brief, actionable guidance that can be used in real time with the patient in the physician’s office. For evidence-based guidelines on medication management for patients with SCI, family physicians are encouraged to use curated resources, such as Actionable Nuggets, to enhance care provided to these patients.

Acknowledgment

This work was supported by the Rick Hansen Foundation and the Mark S. Lodge Foundation.

Notes

Editor’s key points

  • ▸ Pain, recurrent urinary tract infections (UTIs), and muscle spasms are common problems seen in primary care among patients with spinal cord injury (SCI) that may require pharmacologic treatment.

  • ▸ Pain medication regimens, including the potential use of multiple medications, must be individualized according to the sources of pain and treatment response.

  • ▸ There is a tendency to overtreat UTIs in patients with SCI. This population has higher resistance rates to a number of usual treatments for bladder infection.

  • ▸ Spasticity can have a substantial impact on activities of daily life for patients with SCI. It is often related to an underlying problem, such as pain or a UTI, thus treating concomitant conditions may also reduce spasticity.

Footnotes

  • Contributors

    All authors contributed to the literature review and interpretation and to preparing the manuscript for submission.

  • Competing interests

    None declared

  • This article is eligible for Mainpro+ certified Self-Learning credits. To earn credits, go to https://www.cfp.ca and click on the Mainpro+ link.

  • This article has been peer reviewed.

  • Cet article se trouve aussi en français à la page 889.

  • Copyright © 2022 the College of Family Physicians of Canada

References

  1. 1.↵
    1. Gupta S,
    2. McColl MA,
    3. Smith K,
    4. Guilcher SJT.
    Prescription medication cost, insurance coverage, and cost-related nonadherence among people with spinal cord injury in Canada. Spinal Cord 2020;58(5):587-95. Epub 2020 Jan 3.
    OpenUrl
  2. 2.↵
    1. Gupta S,
    2. McColl MA,
    3. Smith K,
    4. McColl A.
    Prescribing patterns for treating common complications of spinal cord injury. J Spinal Cord Med 2021 May 6. Epub ahead of print.
  3. 3.↵
    1. McColl MA,
    2. Aiken A,
    3. Smith K,
    4. McColl A,
    5. Green M,
    6. Godwin M, et al.
    Actionable nuggets. Knowledge translation tool for the needs of patients with spinal cord injury. Can Fam Physician 2015;61:e240-8. Available from: https://www.cfp.ca/content/cfp/61/5/e240.full.pdf. Accessed 2022 Nov 24.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. McColl MA,
    2. Gupta S,
    3. Smith K,
    4. McColl A.
    Promoting long-term health among people with spinal cord injury: what’s new? Int J Environ Res Public Health 2017;14(12):1520.
    OpenUrl
  5. 5.↵
    Actionable Nuggets [website]. Kingston, ON: Actionable Nuggets for Spinal Cord Injury; 2022. Available from: https://actionnuggets.ca/. Accessed 2022 Oct 31.
  6. 6.↵
    1. Müller R,
    2. Brinkhof MWG,
    3. Arnet U,
    4. Hinrichs T,
    5. Landmann G,
    6. Jordan X, et al.
    Prevalence and associated factors of pain in the Swiss spinal cord injury population. Spinal Cord 2017;55(4):346-54. Epub 2016 Nov 15.
    OpenUrl
  7. 7.↵
    1. Bryce TN,
    2. Richards JS,
    3. Bombardier CH,
    4. Dijkers MP,
    5. Fann JR,
    6. Brooks L, et al.
    Screening for neuropathic pain after spinal cord injury with the Spinal Cord Injury Pain Instrument (SCIPI): a preliminary validation study. Spinal Cord 2014;52(5):407-12. Epub 2014 Mar 11.
    OpenUrlPubMed
  8. 8.↵
    1. Mu A,
    2. Weinberg E,
    3. Moulin DE,
    4. Clarke H.
    Pharmacologic management of chronic neuropathic pain. Review of the Canadian Pain Society consensus statement. Can Fam Physician 2017;63:844-52.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Varghese J,
    2. Anderson KD,
    3. Widerström-Noga E,
    4. Mehan U.
    A primary care provider’s guide to pain after spinal cord injury: screening and management. Top Spinal Cord Inj Rehabil 2020;26(3):133-43.
    OpenUrl
  10. 10.↵
    1. Guy SD,
    2. Mehta S,
    3. Casalino A,
    4. Côté I,
    5. Kras-Dupuis A,
    6. Moulin DE, et al.
    The CanPain SCI clinical practice guidelines for rehabilitation management of neuropathic pain after spinal cord: recommendations for treatment. Spinal Cord 2016;54(Suppl 1):S14-23.
    OpenUrl
  11. 11.↵
    1. Mehta S,
    2. Guy S,
    3. Lam T,
    4. Teasell R,
    5. Loh E.
    Antidepressants are effective in decreasing neuropathic pain after SCI: a meta-analysis. Top Spinal Cord Inj Rehabil 2015;21(2):166-73. Epub 2015 Apr 12.
    OpenUrl
  12. 12.↵
    1. Carbone LD,
    2. Chin AS,
    3. Lee TA,
    4. Burns SP,
    5. Svircev JN,
    6. Hoenig HM, et al.
    The association of opioid use with incident lower extremity fractures in spinal cord injury. J Spinal Cord Med 2013;36(2):91-6.
    OpenUrl
  13. 13.↵
    1. Busse JW,
    2. Craigie S,
    3. Juurlink DN,
    4. Buckley DN,
    5. Wang L,
    6. Couban RJ, et al.
    Guideline for opioid therapy and chronic noncancer pain. CMAJ 2017;189(81):E659-66.
    OpenUrlFREE Full Text
  14. 14.↵
    Opioid Manager [website]. Hamilton, ON: McMaster University; 2011. Available from: https://healthsci.mcmaster.ca/npc/opioid-manager. Accessed 2022 Nov 17.
  15. 15.↵
    1. Hagen EM,
    2. Rekand T.
    Management of neuropathic pain associated with spinal cord injury. Pain Ther 2015;4(1):51-65. Epub 2015 Mar 6.
    OpenUrl
  16. 16.↵
    1. Saulino M.
    Spinal cord injury pain. Phys Med Rehabil Clin N Am 2014;25(2):397-410. Epub 2014 Mar 14.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Rekand T,
    2. Hagen EM,
    3. Grønning M.
    Spasticity following spinal cord injury. Tidsskr Nor Laegeforen 2012;132(8):970-3.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Elbasiouny SM,
    2. Moroz D,
    3. Bakr MM,
    4. Mushahwar VK.
    Management of spasticity after spinal cord injury: current techniques and future directions. Neurorehabil Neural Repair 2010;24(1):23-33. Epub 2009 Sep 1.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Kohout RK,
    2. Saunders LL,
    3. Krause JS.
    The relationship between prescription medication use and ability to ambulate distances after spinal cord injury. Arch Phys Med Rehabil 2011;92(8):1246-9.
    OpenUrlPubMed
  20. 20.↵
    1. Nicolle LE.
    Urinary tract infections in patients with spinal injuries. Curr Infect Dis Rep 2014;16(1):390.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. McColl MA,
    2. Smith K,
    3. McColl A.
    Recognizing urinary tract infections in SCI. Kingston, ON: Actionable Nuggets for Spinal Cord Injury; 2019. Available from: https://actionnuggets.ca/13-recognizing-urinary-tract-infections-in-sci/. Accessed 2022 Oct 31.
  22. 22.↵
    1. Clarke K,
    2. Hall CL,
    3. Wiley Z,
    4. Chernetsky Tejedor S,
    5. Kim JS,
    6. Reif L, et al.
    Catheter-associated urinary tract infections in adults: diagnosis, treatment, and prevention. J Hosp Med 2020;15(9):552-6.
    OpenUrl
  23. 23.↵
    1. Hill TC,
    2. Baverstock R,
    3. Carlson KV,
    4. Estey EP,
    5. Gray GJ,
    6. Hill DC, et al.
    Best practices for the treatment and prevention of urinary tract infection in the spinal cord injured population: the Alberta context. Can Urol Assoc J 2013;7(3-4):122-30.
    OpenUrl
  24. 24.↵
    1. Muth C,
    2. Blom JW,
    3. Smith SM,
    4. Johnell K,
    5. Gonzalez-Gonzalez AI,
    6. Nguyen TS, et al.
    Evidence supporting the best clinical management of patients with multimorbidity and polypharmacy: a systematic guideline review and expert consensus. J Intern Med 2019;285(3):272-88. Epub 2018 Dec 10. Erratum in: J Intern Med 2019;286(4):487.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Family Physician: 68 (12)
Canadian Family Physician
Vol. 68, Issue 12
1 Dec 2022
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Prescribing for common complications of spinal cord injury
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Prescribing for common complications of spinal cord injury
Mary Ann McColl, Shikha Gupta, Alexander McColl, Karen Smith
Canadian Family Physician Dec 2022, 68 (12) 885-888; DOI: 10.46747/cfp.6812885

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Prescribing for common complications of spinal cord injury
Mary Ann McColl, Shikha Gupta, Alexander McColl, Karen Smith
Canadian Family Physician Dec 2022, 68 (12) 885-888; DOI: 10.46747/cfp.6812885
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Case description
    • Sources of information
    • Main message
    • Case resolution
    • Conclusion
    • Acknowledgment
    • Notes
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • Health care crisis in Canada
  • Prescriptions pour les complications courantes des lésions de la moelle épinière
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Parkinson disease primer, part 2: management of motor and nonmotor symptoms
  • Parkinson disease primer, part 1: diagnosis
Show more Clinical Review

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2023 by The College of Family Physicians of Canada

Powered by HighWire